Robust neutralizing antibodies to SARS-CoV-2 infection persist for months-Reference-Cited by-同舟云学术

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Published:2020-12-04 Issue:6521 Volume:370 Page:1227-1230
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Wajnberg Ania¹^ORCID,Amanat Fatima²³^ORCID,Firpo Adolfo⁴,Altman Deena R.⁵^ORCID,Bailey Mark J.¹,Mansour Mayce¹^ORCID,McMahon Meagan²^ORCID,Meade Philip²³^ORCID,Mendu Damodara Rao⁴,Muellers Kimberly¹^ORCID,Stadlbauer Daniel²^ORCID,Stone Kimberly¹,Strohmeier Shirin²,Simon Viviana²^ORCID,Aberg Judith⁵^ORCID,Reich David L.⁶^ORCID,Krammer Florian²^ORCID,Cordon-Cardo Carlos⁴^ORCID

Affiliation:

1. Department of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

2. Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

3. Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

4. Clinical Microbiology Laboratory, Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

5. Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

6. Department of Anesthesiology, Perioperative and Pain Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Abstract

SARS-CoV-2 antibodies persist As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain. Wajnberg et al. used a cohort of more than 30,000 infected individuals with mild to moderate COVID-19 symptoms to determine the robustness and longevity of the anti–SARS-CoV-2 antibody response. They found that neutralizing antibody titers against the SARS-CoV-2 spike protein persisted for at least 5 months after infection. Although continued monitoring of this cohort will be needed to confirm the longevity and potency of this response, these preliminary results suggest that the chance of reinfection may be lower than is currently feared. Science , this issue p. 1227

Funder

National Institute of Allergy and Infectious Diseases

JPB Foundation

Open Philanthropy Project

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference22 articles.

1. High neutralizing antibody titer in intensive care unit patients with COVID-19

2. Antibody responses to SARS-CoV-2 in patients with COVID-19

3. Serology assays to manage COVID-19